OMDA · XBRL financial data

Omada Health financial statements, every quarter

The same tables from 5 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (OMDA's year ends in late December)

In thousands of dollars	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue from contracts with customers	61,371	68,030	75,846*	78,048	87,835
Cost of revenue	21,065	22,959	22,184*	29,355	24,048
Gross profit	40,306	45,071	53,662*	48,693	63,787
Research and development	10,024	10,301	11,552*	12,697	14,625
General and administrative	12,308	14,340	14,216*	13,990	15,725
Total operating expenses	44,650	47,584	50,381*	53,474	60,238
Operating income (loss)	(4,344)	(2,513)	3,281*	(4,781)	3,549
Interest income	863	2,009	1,891*	1,829	1,759
Interest expense	1,094	353	13*	18	14
Income tax expense (benefit)	0	0	0*	0	0
Net income (loss)	(5,311)	(3,178)	5,159*	(2,970)	5,294
Earnings per share, basic USD per share	(0.24)	(0.06)	—	(0.05)	0.09
Earnings per share, diluted USD per share	(0.24)	(0.06)	—	(0.05)	0.08
Weighted average shares, basic thousands of shares	21,971	57,658	—	58,923	59,685
Weighted average shares, diluted thousands of shares	21,971	57,658	—	58,923	63,947

Fiscal quarters (OMDA's year ends in late December)

In thousands of dollars	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	223,146	198,627	222,036	211,765	221,712
Accounts receivable	33,287	41,446	34,585	39,985	56,573
Inventory	3,469	3,148	4,486	3,831	4,119
Prepaid and other current assets	7,750	8,449	8,288	9,827	8,548
Total current assets	271,105	254,898	272,934	269,427	294,911
Property and equipment, net	6,484	7,537	7,942	8,455	9,098
Right-of-use asset	65	0	0	—	—
Goodwill	13,240	13,240	13,240	13,240	13,240
Total assets	302,971	287,469	305,406	302,798	328,222
Accounts payable	7,403	5,344	10,276	8,100	11,804
Accrued liabilities	25,060	37,622	40,392	31,227	35,978
Total current liabilities	57,988	70,123	75,726	68,680	75,483
Total liabilities	88,757	70,123	75,726	68,680	75,483
Accumulated deficit	(458,725)	(461,903)	(456,744)	(459,714)	(454,420)
Total stockholders' equity	214,214	217,346	229,680	234,118	252,739
Total liabilities and equity	302,971	287,469	305,406	302,798	328,222
Common shares outstanding (cover page) thousands of shares	57,575	57,908	58,925	59,449	61,217

Fiscal quarters (OMDA's year ends in late December)

In thousands of dollars	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(5,311)	(3,178)	5,159*	(2,970)	5,294
Stock-based compensation	2,830*	3,536*	3,745*	4,209	5,631*
Depreciation and amortization	1,352*	1,359*	1,447*	1,508	1,581*
Net cash from operating activities	2,858*	10,133*	21,379*	(11,834)	4,007*
Purchases of property and equipment	271*	537*	199*	78	146*
Net cash from investing activities	(1,250)*	(1,987)*	(1,346)*	(1,557)	(1,664)*
Net cash from financing activities	162,141*	(32,665)*	3,376*	3,120	7,604*
Net change in cash	163,749*	(24,519)*	23,409*	(10,271)	9,947*

SIC 8000 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 8000 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Omada Health	221,712	87,835	4,007*	61.2M	—	Q2 FY26 10-QJun 30, 2026
Pennant Group	15,273	297,984	21,830*	34.9M	—	Q2 FY26 10-QJun 30, 2026
LifeStance Health Group	225,943	435,354	99,912*	382.1M	—	Q2 FY26 10-QJun 30, 2026
U S Physical Therapy	24,887	214,059	34,370*	14.9M	—	Q2 FY26 10-QJun 30, 2026
GeneDx Holdings	60,317	114,440	(28,981)*	29.8M	4.6 quarters	Q2 FY26 10-QJun 30, 2026
Privia Health Group	412,200	not reported	1,100*	127.7M	—	Q2 FY26 10-QJun 30, 2026
Talkspace	39,159	61,672	11,385*	165.8M	—	Q2 FY26 10-QJun 30, 2026
Strata Critical Medical	35,136	74,081	9,458*	89.3M	—	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.